- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04929041
Testen van de toevoeging van bestralingstherapie aan de gebruikelijke behandeling (immunotherapie met of zonder chemotherapie) voor stadium IV niet-kleincellige longkankerpatiënten die PD-L1-negatief zijn
Een gerandomiseerde fase II/III-studie van moderne, op immunotherapie gebaseerde systemische therapie met of zonder SBRT voor PD-L1-negatieve, gevorderde niet-kleincellige longkanker
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Ander: Quality-of-Life Assessment
- Procedure: Biospecimen Collection
- Biologisch: Ipilimumab
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Procedure: Echocardiography Test
- Procedure: Positron Emission Tomography
- Biologisch: Nivolumab
- Straling: Radiation Therapy
- Procedure: Biopsy Procedure
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Verenigde Staten, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Verenigde Staten, 92618
- City of Hope at Irvine Lennar
-
Lancaster, California, Verenigde Staten, 93534
- City of Hope Antelope Valley
-
Marysville, California, Verenigde Staten, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Verenigde Staten, 95355
- Memorial Medical Center
-
Napa, California, Verenigde Staten, 94558
- Providence Queen of The Valley
-
Sacramento, California, Verenigde Staten, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Verenigde Staten, 91030
- City of Hope South Pasadena
-
Truckee, California, Verenigde Staten, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland, California, Verenigde Staten, 91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs, Colorado, Verenigde Staten, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Verenigde Staten, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Verenigde Staten, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Verenigde Staten, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Verenigde Staten, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Verenigde Staten, 80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville, Delaware, Verenigde Staten, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Verenigde Staten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Verenigde Staten, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Verenigde Staten, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura, Florida, Verenigde Staten, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater, Florida, Verenigde Staten, 33756
- Morton Plant Hospital
-
Coral Gables, Florida, Verenigde Staten, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Verenigde Staten, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Verenigde Staten, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Verenigde Staten, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Verenigde Staten, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven, Florida, Verenigde Staten, 33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan, Georgia, Verenigde Staten, 30265
- CTCA at Southeastern Regional Medical Center
-
Savannah, Georgia, Verenigde Staten, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Verenigde Staten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Verenigde Staten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Verenigde Staten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Verenigde Staten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois
-
Danville, Illinois, Verenigde Staten, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Verenigde Staten, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Verenigde Staten, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Verenigde Staten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Verenigde Staten, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Verenigde Staten, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Verenigde Staten, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Verenigde Staten, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Verenigde Staten, 60426
- Ingalls Memorial Hospital
-
Lake Forest, Illinois, Verenigde Staten, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Verenigde Staten, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Verenigde Staten, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Verenigde Staten, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Verenigde Staten, 60462
- University of Chicago Medicine-Orland Park
-
Rockford, Illinois, Verenigde Staten, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Verenigde Staten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Verenigde Staten, 62702
- Springfield Clinic
-
Springfield, Illinois, Verenigde Staten, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Verenigde Staten, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Verenigde Staten, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point, Indiana, Verenigde Staten, 46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames, Iowa, Verenigde Staten, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Verenigde Staten, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Verenigde Staten, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Verenigde Staten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Verenigde Staten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Verenigde Staten, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Verenigde Staten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Verenigde Staten, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Verenigde Staten, 50266
- Mercy Medical Center-West Lakes
-
West Des Moines, Iowa, Verenigde Staten, 50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Verenigde Staten, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford, Maine, Verenigde Staten, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Verenigde Staten, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Verenigde Staten, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Verenigde Staten, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Verenigde Staten, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Verenigde Staten, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Verenigde Staten, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Verenigde Staten, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Verenigde Staten, 48118
- Chelsea Hospital
-
Flint, Michigan, Verenigde Staten, 48503
- Hurley Medical Center
-
Flint, Michigan, Verenigde Staten, 48503
- Genesys Hurley Cancer Institute
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Verenigde Staten, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Verenigde Staten, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Verenigde Staten, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Verenigde Staten, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Verenigde Staten, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Verenigde Staten, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Verenigde Staten, 48764
- MyMichigan Medical Center Tawas
-
West Branch, Michigan, Verenigde Staten, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Verenigde Staten, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth, Minnesota, Verenigde Staten, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, Verenigde Staten, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Verenigde Staten, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Verenigde Staten, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Verenigde Staten, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Verenigde Staten, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Verenigde Staten, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Verenigde Staten, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Verenigde Staten, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Verenigde Staten, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Verenigde Staten, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Verenigde Staten, 59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Verenigde Staten, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Verenigde Staten, 10019
- Mount Sinai West
-
New York, New York, Verenigde Staten, 10029
- Mount Sinai Hospital
-
New York, New York, Verenigde Staten, 10011
- Mount Sinai Chelsea
-
New York, New York, Verenigde Staten, 10075
- Lenox Hill Hospital
-
New York, New York, Verenigde Staten, 10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego, New York, Verenigde Staten, 13126
- Upstate Cancer Center at Oswego
-
Oswego, New York, Verenigde Staten, 13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse, New York, Verenigde Staten, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Verenigde Staten, 13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse, New York, Verenigde Staten, 13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona, New York, Verenigde Staten, 13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Verenigde Staten, 27609
- Duke Cancer Center Raleigh
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton, Oklahoma, Verenigde Staten, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Verenigde Staten, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Verenigde Staten, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Verenigde Staten, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Verenigde Staten, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Verenigde Staten, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Verenigde Staten, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Verenigde Staten, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Verenigde Staten, 17837
- Geisinger Medical Oncology-Lewisburg
-
Reading, Pennsylvania, Verenigde Staten, 19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre, Pennsylvania, Verenigde Staten, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo, Texas, Verenigde Staten, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock, Virginia, Verenigde Staten, 22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver, Washington, Verenigde Staten, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Verenigde Staten, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla, Washington, Verenigde Staten, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston, West Virginia, Verenigde Staten, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland, Wisconsin, Verenigde Staten, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Verenigde Staten, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Verenigde Staten, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Verenigde Staten, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Verenigde Staten, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Verenigde Staten, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Verenigde Staten, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Verenigde Staten, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Verenigde Staten, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Verenigde Staten, 54476
- Marshfield Medical Center - Weston
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Andere namen:
Undergo blood sample collection
Andere namen:
Given IV
Andere namen:
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Undergo ECHO
Andere namen:
Undergo PET
Andere namen:
Given IV
Andere namen:
Undergo tissue biopsy
Andere namen:
|
|
Experimenteel: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Andere namen:
Undergo blood sample collection
Andere namen:
Given IV
Andere namen:
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Undergo ECHO
Andere namen:
Undergo PET
Andere namen:
Given IV
Andere namen:
Undergo radiation therapy
Andere namen:
Undergo tissue biopsy
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
Tijdsspanne: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
Tijdsspanne: From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Kwaliteit van het leven
Tijdsspanne: Tot 5 jaar
|
Tot 5 jaar
|
|
|
PFS
Tijdsspanne: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
Tijdsspanne: Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
Tijdsspanne: Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Christine M Bestvina, Alliance for Clinical Trials in Oncology
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Longziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Carcinoom
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Adenocarcinoom van de longen
- Longneoplasmata
- Carcinoom, niet-kleincellige long
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Onderzoekstechnieken
- Therapeutica
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Chirurgische procedures, operatief
- Cytologische technieken
- Cytodiagnose
- Biologische factoren
- Fysieke fenomeen
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Diagnostische technieken, chirurgisch
- Chemie -technieken, analytisch
- Spectrumanalyse
- Receptoren, celoppervlak
- Membraaneiwitten
- Antigenen
- Antigenen, oppervlak
- Biomarkers
- Receptoren, immunologisch
- Antigenen, differentiatie, T-lymfocyt
- Antigenen, differentiatie
- Immuun checkpoint -eiwitten
- Costimulatoire en remmende T-celreceptoren
- Nivolumab
- Ipilimumab
- Radiotherapie
- Bestraling
- Biopsie
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- CTLA-4 antigeen
Andere studie-ID-nummers
- NCI-2021-06042
- U10CA180821 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2021-06042 (Register-ID: CTRP (Clinical Trial Reporting Program))
- A082002 (Andere identificatie: CTEP)
- A082002 (Andere identificatie: Alliance for Clinical Trials in Oncology)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .